Common Molecular Pathways in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Trends in Molecular Medicine

Volumn 22, Issue 9, 2016, Pages 769-783

  Weishaupt, Jochen H ^a   Hyman, Tony ^b   Dikic, Ivan ^c,d  

^a UNIVERSITY OF ULM   (Germany)

^b MAX PLANCK INSTITUTE OF MOLECULAR CELL BIOLOGY AND GENETICS   (Germany)

^c GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

^d GOETHE UNIVERSITY   (Germany)

Author keywords

amyotrophic lateral sclerosis; autophagy; frontotemporal dementia; genetics; RNA granules

Indexed keywords

PRION PROTEIN; RNA; RNA BINDING PROTEIN; PROTEIN AGGREGATE;

AGE; AMYOTROPHIC LATERAL SCLEROSIS; DEGENERATIVE DISEASE; FRONTOTEMPORAL DEMENTIA; HUMAN; HUMAN GENETICS; LIQUID; MOLECULAR DIAGNOSIS; NEUROPATHOLOGY; NONHUMAN; PHASE SEPARATION; PHENOTYPE; PROTEIN AGGREGATION; REVIEW; RNA PROCESSING; ANIMAL; AUTOPHAGY; GENETICS; METABOLISM; PATHOLOGY;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; AUTOPHAGY; FRONTOTEMPORAL DEMENTIA; HUMANS; PROTEIN AGGREGATES; RNA;

EID: 84990925109     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2016.07.005     Document Type: Review

References (100)

1. 1 Uenal, H., et al. Incidence and geographical variation of amyotrophic lateral sclerosis (ALS) in Southern Germany—completeness of the ALS registry Swabia. PLoS ONE, 9, 2014, e93932.
2. 2 Onyike, C.U., Diehl-Schmid, J., The epidemiology of frontotemporal dementia. Int. Rev. Psychiatry 25 (2013), 130–137.
3. 3 Kiernan, M.C., et al. Amyotrophic lateral sclerosis. Lancet 377 (2011), 942–955.
4. 4 Burrell, J.R., et al. The frontotemporal dementia-motor neuron disease continuum. Lancet, 2016, 10.1016/S0140-6736(16)00737-6 Published online March 14, 2016.
5. 5 Neumann, M., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314 (2006), 130–133.
6. 6 Sreedharan, J., et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319 (2008), 1668–1672.
7. 7 Kabashi, E., et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet. 40 (2008), 572–574.
8. 8 DeJesus-Hernandez, M., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72 (2011), 245–256.
9. 9 Renton, A.E., et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72 (2011), 257–268.
10. 10 Johnson, J.O., et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 68 (2010), 857–864.
11. 11 Freischmidt, A., et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat. Neurosci. 18 (2015), 631–636.
12. 12 Renton, A.E., et al. State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 17 (2014), 17–23.
13. 13 Bruijn, L.I., et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 281 (1998), 1851–1854.
14. 14 Kwiatkowski, T.J. Jr., et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323 (2009), 1205–1208.
15. 15 Vance, C., et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323 (2009), 1208–1211.
16. 16 Johnson, J.O., et al. Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nat. Neurosci. 17 (2014), 664–666.
17. 17 Kim, H.J., et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature 495 (2013), 467–473.
18. 18 Johnson, B.S., et al. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J. Biol. Chem. 284 (2009), 20329–20339.
19. 19 Deng, H., et al. The role of FUS gene variants in neurodegenerative diseases. Nat. Rev. Neurol. 10 (2014), 337–348.
20. 20 Mackenzie, I.R., et al. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 9 (2010), 995–1007.
21. 21 March, Z.M., et al. Prion-like domains as epigenetic regulators, scaffolds for subcellular organization, and drivers of neurodegenerative disease. Brain Res., 2016, 10.1016/j.brainres.2016.02.037 Published online March 18, 2016.
22. 22 Shorter, J., Taylor, J.P., Disease mutations in the prion-like domains of hnRNPA1 and hnRNPA2/B1 introduce potent steric zippers that drive excess RNP granule assembly. Rare Dis., 1, 2013, e25200.
23. 23 Waibel, S., et al. Truncating mutations in FUS/TLS give rise to a more aggressive ALS-phenotype than missense mutations: a clinico-genetic study in Germany. Eur. J. Neurol. 20 (2013), 540–546.
24. 24 Dormann, D., et al. ALS-associated fused in sarcoma (FUS) mutations disrupt transportin-mediated nuclear import. EMBO J. 29 (2010), 2841–2857.
25. 25 Ince, P.G., et al. Familial amyotrophic lateral sclerosis with a mutation in exon 4 of the Cu/Zn superoxide dismutase gene: pathological and immunocytochemical changes. Acta Neuropathol. 92 (1996), 395–403.
26. 26 Bäumer, D., et al. Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations. Neurology 75 (2010), 611–618.
27. 27 Neumann, M., et al. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain 132 (2009), 2922–2931.
28. 28 Dormann, D., et al. Arginine methylation next to the PY-NLS modulates transportin binding and nuclear import of FUS. EMBO J. 31 (2012), 4258–4275.
29. 29 Suárez-Calvet, M., et al. Monomethylated and unmethylated FUS exhibit increased binding to transportin and distinguish FTLD-FUS from ALS-FUS. Acta Neuropathol. 131 (2016), 587–604.
30. 30 Prusiner, S.B., Prions. Proc. Natl. Acad. Sci. U.S.A. 95 (1998), 13363–13383.
31. 31 Ravits, J.M., La Spada, A.R., ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology 73 (2009), 805–811.
32. 32 Brettschneider, J., et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann. Neurol. 74 (2013), 20–38.
33. 33 Nonaka, T., et al. Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep. 4 (2013), 124–134.
34. 34 Feiler, M.S., et al. TDP-43 is intercellularly transmitted across axon terminals. J. Cell Biol. 211 (2015), 897–911.
35. 35 Bidhendi, E.E., et al. Two superoxide dismutase prion strains transmit amyotrophic lateral sclerosis-like disease. J. Clin. Invest. 126 (2016), 2249–2253.
36. 36 Polymenidou, M., et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat. Neurosci. 14 (2011), 459–468.
37. 37 Ling, J.P., et al. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science 349 (2015), 650–655.
38. 38 Freischmidt, A., et al. Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers. Brain 137 (2014), 2938–2950.
39. 39 Freischmidt, A., et al. Systemic dysregulation of TDP-43 binding microRNAs in amyotrophic lateral sclerosis. Acta Neuropathol. Commun., 1, 2013, 42.
40. 40 Shukla, S., Parker, R., Hypo- and hyper-assembly diseases of RNA-protein complexes. Trends Mol. Med. 22 (2016), 615–628.
41. 41 Li, Y.R., et al. Stress granules as crucibles of ALS pathogenesis. J. Cell Biol. 201 (2013), 361–372.
42. 42 Monahan, Z., et al. Stress granules at the intersection of autophagy and ALS. Brain Res., 2016, 10.1016/j.brainres.2016.05.022 Published online May 13, 2016.
43. 43 Kedersha, N., et al. Stress granules and processing bodies are dynamically linked sites of mRNP remodeling. J. Cell Biol. 169 (2005), 871–884.
44. 44 Brangwynne, C.P., et al. Germline P granules are liquid droplets that localize by controlled dissolution/condensation. Science 324 (2009), 1729–1732.
45. 45 Guo, L., Shorter, J., It's raining liquids: RNA tunes viscoelasticity and dynamics of membraneless organelles. Mol. Cell 60 (2015), 189–192.
46. 46 Lin, Y., et al. Formation and maturation of phase-separated liquid droplets by RNA-binding proteins. Mol. Cell 60 (2015), 208–219.
47. 47 Zhang, H., et al. RNA controls PolyQ protein phase transitions. Mol. Cell 60 (2015), 220–230.
48. 48 Patel, A., et al. A liquid-to-solid phase transition of the ALS protein FUS accelerated by disease mutation. Cell 162 (2015), 1066–1077.
49. 49 Molliex, A., et al. Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization. Cell 163 (2015), 123–133.
50. 50 Linkus, B., et al. Telomere shortening leads to earlier age of onset in ALS mice. Aging (Albany NY) 8 (2016), 382–393.
51. 51 Wang, W.Y., et al. Interaction of FUS and HDAC1 regulates DNA damage response and repair in neurons. Nat. Neurosci. 16 (2013), 1383–1391.
52. 52 Qiu, H., et al. ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defects. J. Clin. Invest. 124 (2014), 981–999.
53. 53 Fang, X., et al. The NEK1 interactor, C21ORF2, is required for efficient DNA damage repair. Acta Biochim. Biophys. Sin. (Shanghai) 47 (2015), 834–841.
54. 54 Ktistakis, N.T., Tooze, S.A., Digesting the expanding mechanisms of autophagy. Trends Cell Biol. 26 (2016), 624–635.
55. 55 Stolz, A., et al. Cargo recognition and trafficking in selective autophagy. Nat. Cell Biol. 16 (2014), 495–501.
56. 56 Khaminets, A., et al. Ubiquitin-dependent and independent signals in selective autophagy. Trends Cell Biol. 26 (2016), 6–16.
57. 57 Wild, P., et al. Phosphorylation of the autophagy receptor optineurin restricts Salmonella growth. Science 333 (2011), 228–233.
58. 58 Heo, J.M., et al. The PINK1-PARKIN mitochondrial ubiquitylation pathway drives a program of OPTN/NDP52 recruitment and TBK1 activation to promote mitophagy. Mol. Cell 60 (2015), 7–20.
59. 59 Lazarou, M., et al. The ubiquitin kinase PINK1 recruits autophagy receptors to induce mitophagy. Nature 524 (2015), 309–314.
60. 60 Richter, B., et al. Phosphorylation of OPTN by TBK1 enhances its binding to Ub chains and promotes selective autophagy of damaged mitochondria. Proc. Natl. Acad. Sci. U.S.A. 113 (2016), 4039–4044.
61. 61 Cirulli, E.T., et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science 347 (2015), 1436–1441.
62. 62 Ahmad, L., et al. Human TBK1: a gatekeeper of neuroinflammation. Trends Mol. Med. 22 (2016), 511–527.
63. 63 Maruyama, H., et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 465 (2010), 223–226.
64. 64 Fecto, F., et al. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch. Neurol. 68 (2011), 1440–1446.
65. 65 Skibinski, G., et al. Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat. Genet. 37 (2005), 806–808.
66. 66 Parkinson, N., et al. ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B). Neurology 67 (2006), 1074–1077.
67. 67 Korac, J., et al. Ubiquitin-independent function of optineurin in autophagic clearance of protein aggregates. J. Cell Sci. 126 (2013), 580–592.
68. 68 Wong, Y.C., Holzbaur, E.L., Optineurin is an autophagy receptor for damaged mitochondria in parkin-mediated mitophagy that is disrupted by an ALS-linked mutation. Proc. Natl. Acad. Sci. U.S.A. 111 (2014), E4439–E4448.
69. 69 Zhang, C., Cuervo, A.M., Restoration of chaperone-mediated autophagy in aging liver improves cellular maintenance and hepatic function. Nat. Med. 14 (2008), 959–965.
70. 70 Buchan, J.R., et al. Eukaryotic stress granules are cleared by autophagy and Cdc48/VCP function. Cell 153 (2013), 1461–1474.
71. 71 Gijselinck, I., et al. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol. 11 (2012), 54–65.
72. 72 Ash, P.E., et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 77 (2013), 639–646.
73. 73 Mori, K., et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 339 (2013), 1335–1338.
74. 74 Freibaum, B.D., et al. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature 525 (2015), 129–133.
75. 75 Jovičić, A., et al. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat. Neurosci. 18 (2015), 1226–1229.
76. 76 Sellier, C., et al. Loss of C9ORF72 impairs autophagy and synergizes with polyQ Ataxin-2 to induce motor neuron dysfunction and cell death. EMBO J. 35 (2016), 1276–1297.
77. 77 Sullivan, P.M., et al. The ALS/FTLD associated protein C9orf72 associates with SMCR8 and WDR41 to regulate the autophagy-lysosome pathway. Acta Neuropathol. Commun., 4, 2016, 51.
78. 78 Spang, N., et al. RAB3GAP1 and RAB3GAP2 modulate basal and rapamycin-induced autophagy. Autophagy 10 (2014), 2297–2309.
79. 79 Münch, C., Ludolph, A.C., Pharmacological treatment of ALS. Neurol. Neurochir. Pol. 35 (2001), 41–50.
80. 80 Miller, T.M., et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 12 (2013), 435–442.
81. 81 Smith, R.A., et al. Antisense oligonucleotide therapy for neurodegenerative disease. J. Clin. Invest. 116 (2006), 2290–2296.
82. 82 Beck, J., et al. Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. Am. J. Hum. Genet. 92 (2013), 345–353.
83. 83 Deng, H.X., et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 477 (2011), 211–215.
84. 84 Puls, I., et al. Mutant dynactin in motor neuron disease. Nat. Genet. 33 (2003), 455–456.
85. 85 Wu, C.H., et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature 488 (2012), 499–503.
86. 86 Figlewicz, D.A., et al. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum. Mol. Genet. 3 (1994), 1757–1761.
87. 87 Al-Chalabi, A., et al. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum. Mol. Genet. 8 (1999), 157–164.
88. 88 Smith, B.N., et al. Exome-wide rare variant analysis identifies TUBA4A mutations associated with familial ALS. Neuron 84 (2014), 324–331.
89. 89 Brenner, D., et al. NEK1 mutations in familial amyotrophic lateral sclerosis. Brain, 139, 2016, e28.
90. 90 van Rheenen, W. et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat. Genet. http://dx.doi.org/10.1038/ng.3622. Published online July 25, 2016.
91. 91 Orlacchio, A., et al. SPATACSIN mutations cause autosomal recessive juvenile amyotrophic lateral sclerosis. Brain 133 (2010), 591–598.
92. 92 Nishimura, A.L., et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am. J. Hum. Genet. 75 (2004), 822–831.
93. 93 Yang, Y., et al. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat. Genet. 29 (2001), 160–165.
94. 94 Hadano, S., et al. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat. Genet. 29 (2001), 166–173.
95. 95 Hutton, M., et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393 (1998), 702–705.
96. 96 Spillantini, M.G., et al. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. U.S.A. 95 (1998), 7737–7741.
97. 97 Poorkaj, P., et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 43 (1998), 815–825.
98. 98 Rosen, D.R., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362 (1993), 59–62.
99. 99 Cruts, M., et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442 (2006), 920–924.
100. 100 Baker, M., et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442 (2006), 916–919.